DeciBio Ventures flags pharma services sector push into AI-enabled clinical development in Q3 2026 roundup

By Public Technologies
  • DeciBio Ventures’ Q3 2026 pharma services round-up flagged accelerating AI adoption across clinical development platforms.
  • ICON entered a multi-year collaboration with Anthropic to embed Claude into Orbis for trial operations, including site selection.
  • Samsung Biologics launched an all-cash tender offer of $1.8 billion for PolyPeptide, targeting peptide capacity tied to GLP-1 demand.
  • Tempus AI agreed to acquire Personalis to add MRD testing, tightening integration across its precision oncology platform.
  • Fortrea agreed to buy Worldwide’s early phase services unit for $45 million, expanding early-stage capabilities via lab and clinic assets.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DeciBio Ventures published the original content used to generate this news brief on October 13, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk